DR. PRANEETH BARATAM MD
Prescription History 1487970570
Internal Medicine - Hematology in Charleston, SC

NPI Status: Active since April 14, 2010

Contact Information

171 ASHLEY AVE
CHARLESTON, SC
ZIP 29425
Phone: (843) 792-1414

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. PRANEETH BARATAM MD, an active Hematology specialist practicing in Charleston, SC. Our medical registry currently tracks 21 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 583 documented patient claims. Among these therapy options, the most frequently utilized medication is Idhifa, which accounts for 66 claims alone.


Acyclovir

Generic Formulation: AcyclovirSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 52
30-Day Fills 56.0
Days Supply 1,680
SC State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills38.0
Peer Average Days Supply1,035
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 126.1% higher than the standard regional baseline profile for SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $915.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.60

State Avg Cost Per Claim

$23.57

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.

Therapeutic Applications

Acyclovir is used to treat infections caused by certain types of viruses. It treats cold sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster), and chickenpox. This medication is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, acyclovir is used to help reduce the number of future episodes. Acyclovir is an antiviral drug. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Acyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal. In addition, in people with a weakened immune system, acyclovir can decrease the risk of the virus spreading to other parts of the body and causing serious infections.

Allopurinol

Generic Formulation: AllopurinolSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 16
30-Day Fills 19.0
Days Supply 570
SC State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills131.1
Peer Average Days Supply3,869
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.4% less volume than the regional standard for practitioners inside SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $148.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$9.29

State Avg Cost Per Claim

$14.81

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.

Therapeutic Applications

Allopurinol is used to treat gout and certain types of kidney stones. It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy. These patients can have increased uric acid levels due to release of uric acid from the dying cancer cells. Allopurinol works by reducing the amount of uric acid made by the body. Increased uric acid levels can cause gout and kidney problems.

Ciprofloxacin Hcl

Generic Formulation: Ciprofloxacin HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 420
SC State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills30.1
Peer Average Days Supply253
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 51.7% less volume than the regional standard for practitioners inside SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $325.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.25

State Avg Cost Per Claim

$7.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A broad-spectrum antimicrobial carboxyfluoroquinoline.

Therapeutic Applications

This medication is used to treat eye infections. Ciprofloxacin belongs to a class of drugs called quinolone antibiotics. It works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Gleevec

Generic Formulation: Imatinib MesylateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 17
30-Day Fills 19.0
Days Supply 570
SC State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills21.2
Peer Average Days Supply636
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $126,818.23 across this reporting matrix range.

Provider Avg Cost Per Claim

$7,459.90

State Avg Cost Per Claim

$10,775.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome).

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 23
30-Day Fills 47.9
Days Supply 1,438
SC State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills59.3
Peer Average Days Supply1,749
Conservative Utilization

This provider writes prescriptions for this formulation 28.1% less frequently than the standard regional baseline metric for practitioners inside SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,447.03 across this reporting matrix range.

Provider Avg Cost Per Claim

$62.91

State Avg Cost Per Claim

$37.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Iclusig

Generic Formulation: Ponatinib HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 18
30-Day Fills 22.0
Days Supply 660
SC State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills33.0
Peer Average Days Supply990
Conservative Utilization

This provider writes prescriptions for this formulation 45.5% less frequently than the standard regional baseline metric for practitioners inside SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $436,844.47 across this reporting matrix range.

Provider Avg Cost Per Claim

$24,269.14

State Avg Cost Per Claim

$24,745.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Ponatinib is used to treat certain types of blood cancer (chronic myelogenous leukemia-CML, acute lymphoblastic leukemia-ALL). It works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.

Idhifa

Generic Formulation: Enasidenib MesylateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 66
30-Day Fills 66.0
Days Supply 1,980
SC State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills30.5
Peer Average Days Supply915
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 120.0% higher than the standard regional baseline profile for SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,132,915.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$32,316.90

State Avg Cost Per Claim

$29,234.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat a certain type of blood cell cancer (acute myeloid leukemia-AML). Enasidenib works by helping your bone marrow grow normal blood cells so you will need fewer blood transfusions.

Imatinib Mesylate

Generic Formulation: Imatinib MesylateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 660
SC State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills23.5
Peer Average Days Supply677
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $43,767.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,989.43

State Avg Cost Per Claim

$1,985.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome).

Inrebic

Generic Formulation: Fedratinib DihydrochlorideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
SC State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.3
Peer Average Days Supply596
Conservative Utilization

This provider writes prescriptions for this formulation 45.0% less frequently than the standard regional baseline metric for practitioners inside SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $201,126.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$18,284.20

State Avg Cost Per Claim

$17,834.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat a certain type of cancer (myelofibrosis). Fedratinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Jakafi

Generic Formulation: Ruxolitinib PhosphateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 54
30-Day Fills 54.0
Days Supply 1,612
SC State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.4
Peer Average Days Supply669
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 145.5% higher than the standard regional baseline profile for SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $883,545.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$16,361.95

State Avg Cost Per Claim

$15,886.81

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bone marrow disorders (myelofibrosis, polycythemia vera). It works by blocking your body from producing substances called growth factors. Growth factors cause cells to grow and divide, and cause the blood cell and spleen problems found in these disorders. Ruxolitinib belongs to a class of drugs known as kinase inhibitors. Though not a cure for these disorders, ruxolitinib may help with some of the symptoms, including abdominal discomfort, pain under left ribs, early feelings of fullness from meals, night sweats, itching, and bone/muscle pain. Ruxolitinib is also used to treat a certain problem that may occur after certain stem cell or bone marrow transplants (graft versus host disease). It works by weakening your body's defense system (immune system).

Mirtazapine

Generic Formulation: MirtazapineSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
SC State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills67.6
Peer Average Days Supply1,876
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 71.1% less volume than the regional standard for practitioners inside SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $340.38 across this reporting matrix range.

Provider Avg Cost Per Claim

$26.18

State Avg Cost Per Claim

$21.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.

Therapeutic Applications

Mirtazapine is used to treat depression. It improves mood and feelings of well-being. Mirtazapine is an antidepressant that works by restoring the balance of natural chemicals (neurotransmitters) in the brain.

Posaconazole

Generic Formulation: PosaconazoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 44
30-Day Fills 44.0
Days Supply 1,292
SC State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills15.0
Peer Average Days Supply450
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 193.3% higher than the standard regional baseline profile for SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $124,285.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,824.67

State Avg Cost Per Claim

$3,139.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Posaconazole is used to prevent certain fungal infections in patients who have severely weakened immune systems (such as patients who have had chemotherapy). It belongs to a class of drugs known as azole antifungals. It works by stopping the growth of fungi.

Prevymis

Generic Formulation: LetermovirSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.0
Days Supply 588
SC State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.0
Peer Average Days Supply476
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $152,760.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$7,274.33

State Avg Cost Per Claim

$7,056.43

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received a bone marrow transplant. CMV disease can lead to serious infections in the body, including an infection in the eye, called CMV retinitis, that can cause blindness. Letermovir is an anti-viral drug. It works by stopping the growth of the virus.

Scemblix

Generic Formulation: Asciminib HydrochlorideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 38
30-Day Fills 38.0
Days Supply 1,140
SC State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills16.0
Peer Average Days Supply480
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 137.5% higher than the standard regional baseline profile for SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,794,866.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$47,233.33

State Avg Cost Per Claim

$14,764.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Asciminib is used to treat a certain type of cancer (chronic myeloid leukemia-CML). Asciminib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Sprycel

Generic Formulation: DasatinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 31
30-Day Fills 31.0
Days Supply 930
SC State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills20.3
Peer Average Days Supply607
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 63.2% higher than the standard regional baseline profile for SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $382,261.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$12,331.02

State Avg Cost Per Claim

$13,864.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB.

Therapeutic Applications

This medication is used to treat certain types of cancer (chronic myeloid leukemia-CML, acute lymphoblastic leukemia-ALL). It works by slowing or stopping the growth of cancer cells.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 12.8
Days Supply 316
SC State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills27.4
Peer Average Days Supply320
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.0% less volume than the regional standard for practitioners inside SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $38.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$3.49

State Avg Cost Per Claim

$5.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Tasigna

Generic Formulation: Nilotinib HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 24
30-Day Fills 24.0
Days Supply 672
SC State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.9
Peer Average Days Supply506
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 41.2% more claims than the standard regional baseline profile for SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $172,980.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$7,207.53

State Avg Cost Per Claim

$14,788.29

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Nilotinib is used to treat a certain type of blood cancer (chronic myelogenous leukemia-CML). It works by slowing or stopping the growth of cancer cells.

Tibsovo

Generic Formulation: IvosidenibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 32
30-Day Fills 32.0
Days Supply 960
SC State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills31.0
Peer Average Days Supply930
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,114,914.04 across this reporting matrix range.

Provider Avg Cost Per Claim

$34,841.06

State Avg Cost Per Claim

$32,856.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat a certain type of blood cell cancer (acute myeloid leukemia-AML). Ivosidenib works by helping your bone marrow grow normal blood cells so you will need fewer blood transfusions. Ivosidenib is also used to treat bile duct cancer. It works by slowing the growth of cancer cells.

Venclexta

Generic Formulation: VenetoclaxSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 381
SC State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills21.5
Peer Average Days Supply589
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $33,415.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,518.88

State Avg Cost Per Claim

$8,679.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of cancer (chronic lymphocytic leukemia-CLL, small lymphocytic lymphoma-SLL, acute myeloid leukemia-AML). Venetoclax is a drug that works by helping to slow or stop the growth of cancer cells.

Vonjo

Generic Formulation: Pacritinib CitrateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 660
SC State Average Benchmarks
Peer Average Claims--
Peer Average 30-Day Fills--
Peer Average Days Supply--

Provider Avg Cost Per Claim

$19,553.27

State Avg Cost Per Claim

--

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat a certain bone marrow disorder (myelofibrosis). It works by blocking your body from producing substances called growth factors. Pacritinib belongs to a class of drugs known as kinase inhibitors.

Xospata

Generic Formulation: Gilteritinib FumarateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 32
30-Day Fills 32.0
Days Supply 960
SC State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills36.0
Peer Average Days Supply1,080
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $710,485.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$22,202.68

State Avg Cost Per Claim

$20,598.11

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Gilteritinib is used to treat acute myeloid leukemia (AML). It works by slowing or stopping the growth of cancer cells.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. PRANEETH BARATAM MD provides transparency into local medical care patterns within Charleston, SC.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.